VANCOUVER, British Columbia, Apr 19, 2012 (GlobeNewswire via COMTEX) --QLT Inc. (Nasdaq:QLTI) (TSX:QLT) today announced that it will release financial results for the first quarter ended March 31, 2012 on Thursday, May 3, 2012.
Company management will host an investor conference call to discuss first quarter results and review recent accomplishments on Thursday, May 3, 2012 at 8:30 a.m. ET (5:30 a.m. PT). The call will be broadcast live via the Internet at www.qltinc.com. To participate on the call, please dial 1-800-319-4610 (North America) or 604-638-5340 (International) before 8:30 a.m. ET. A replay of the call will be available via the Internet and also via telephone at 1-800-319-6413 (North America) or 604-638-9010 (International), access code 7157, followed by the "#" sign.
QLT is a biotechnology company dedicated to the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. We are focused on developing our synthetic retinoid program for the treatment of certain inherited retinal diseases, developing our proprietary punctal plug delivery system, as well as U.S. marketing of the commercial product Visudyne(R) for the treatment of wet age-related macular degeneration.
QLT's head office is based in Vancouver, Canada and the Company is publicly traded on NASDAQ (symbol: QLTI) and the Toronto Stock Exchange (symbol: QLT). For more information about the Company's products and developments, please visit our web site at www.qltinc.com.
The QLT Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=6933
Visudyne(R) is a registered trademark of Novartis AG.
This news release was distributed by GlobeNewswire, www.globenewswire.com
SOURCE: QLT Inc.
(Logo: http://media.primezone.com/cache/12188/int/7679.jpg) CONTACT: QLT Inc. Contacts:
office: 604.707.7000 or 1.800.663.5486